SEC Filings
State Street Holds 4.4% Of Acadia — The Drugmaker Faces A Patent Appeal
The passive holding totals 7,650,889 shares, while Acadia awaits a ruling on protection for its NUPLAZID capsule formulation.
Acadia Pharmaceuticals (ACAD) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The passive holding totals 7,650,889 shares, while Acadia awaits a ruling on protection for its NUPLAZID capsule formulation.
SEC Filings
A new US patent allowance for Rett drug trofinetide lets Acadia spread Neuren-licensed intangibles over more years, from $10.9 million to $9.9 million.
Earnings
Management will change the statistics, raters and sites for remlifanserin's late-stage trial but keep patient entry criteria unchanged.
Earnings
The drugmaker narrowed its total revenue range while third-quarter net income fell to $54 million from $72 million.
SEC Filings
Acadia Pharmaceuticals is searching for a new head of research and development after Elizabeth Thompson's retirement took effect Friday.